AFL

Aflac is a scaled supplemental insurer with two durable franchises: Aflac Japan (cancer, medical and life-style products) and Aflac U.S. (worksite/group voluntary benefits), both supported by brand trust and entrenched distribution. Recent go-to-market moves—such as joining Workday Wellness (announced January 15, 2026) and expanding third-party agent reach via Empower Brokerage—should help keep U.S. sales momentum competitive as employers push for easier enrollment and administration. The key strategic tension remains Japan’s maturity and currency sensitivity versus the U.S. opportunity to broaden into group benefits, dental and direct-to-consumer.

Financially, earnings power is solid but headline GAAP can swing due to investment and FX effects: for full-year 2025 Aflac reported net earnings of $3.6B, or $6.82 per diluted share, and adjusted earnings of $4.0B, or $7.49 per diluted share. Capital return is a core part of the equity story, with a $0.61 quarterly dividend (annualized $2.44) and a 43-year record of annual dividend increases. As of April 2, 2026, shares trade around 14.3x trailing EPS with an equity value near $59.7B, which looks reasonable for a high-quality insurer but not obviously “deep value.”

Over the next 12 months, the biggest catalysts are Japan sales/profitability trends and yen moves, plus ongoing buybacks/dividend growth supporting per-share compounding. A near-term event risk is Q1 2026 results (scheduled after the close April 29, 2026), where investors will focus on investment income, claims trends, and any update to 2026 earnings cadence. Execution risk sits in distribution initiatives (Workday/agent channels) translating into sustainable U.S. premium growth rather than just reach.

Recommendation: HOLD. The stock offers shareholder-friendly capital returns and resilient adjusted earnings power, but upside is likely capped near term by Japan/FX variability and a valuation that already reflects much of the quality.